Open AccessP1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Author(s) -
Nastoupil L.,
Morschhauser F.,
Scholz C. W.,
Bishton M.,
Yoon S.S.,
Giri P.,
Wei M. C.,
Knapp A.,
Li C.C.,
Bottos A.,
Li H.,
Purev E.,
Bartlett N. L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847368.92731.fb
Subject(s) - lenalidomide , medicine , rituximab , follicular lymphoma , refractory (planetary science) , phases of clinical research , oncology , lymphoma , gastroenterology , chemotherapy , multiple myeloma , astrobiology , physics